Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | UBE2N | P61088 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.55 |
| ▸ | CDK1 | P06493 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 5/20 | 0.55 |
| ▸ | TEK | Q02763 | 5/20 | 0.55 |
| ▸ | AURKA | O14965 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6749027 | 1.00 | KDM4E (0.62) | KDM4EALDH1A1HPGDUBE2NSMN1; SMN2 | |
| SCHEMBL4525551 | 0.90 | KDM4E (0.60) | KDM4EALDH1A1HPGDUBE2NSMN1; SMN2 | |
| SCHEMBL4531151 | 0.88 | KDM4E (0.60) | KDM4EALDH1A1HPGDUBE2NSMN1; SMN2 | |
| SCHEMBL4525589 | 0.88 | AURKA (0.54) | KDM4EALDH1A1HPGDUBE2NSMN1; SMN2 | |
| SCHEMBL6749031 | 0.88 | AURKA (0.54) | KDM4EALDH1A1HPGDUBE2NSMN1; SMN2 | |
| SCHEMBL4527063 | 0.87 | KDM4E (0.61) | KDM4EALDH1A1HPGDUBE2NSMN1; SMN2 | |
| SCHEMBL4535658 | 0.87 | KDM4E (0.63) | KDM4EALDH1A1HPGDUBE2NSMN1; SMN2 | |
| SCHEMBL4530269 | 0.87 | KDM4E (0.63) | KDM4EALDH1A1HPGDUBE2NSMN1; SMN2 | |
| SCHEMBL4696958 | 0.86 | KDM4E (0.58) | KDM4EALDH1A1HPGDUBE2NSMN1; SMN2 | |
| SCHEMBL4530280 | 0.85 | KDM4E (0.67) | KDM4EALDH1A1HPGDUBE2NSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966217-B1 | NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2013-05-08 | — | — | EP | disclosed |
| EP-1966217-B1 | NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2013-05-08 | — | — | EP | disclosed |
| US-8183246-B2 | Acyclically substituted furopyrimidine derivatives and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-8183246-B2 | Acyclically substituted furopyrimidine derivatives and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-8183246-B2 | Acyclically substituted furopyrimidine derivatives and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-20090318475-A1 | Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2009-12-24 | — | — | US | disclosed |
| US-20090318475-A1 | Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2009-12-24 | — | — | US | disclosed |
| US-20090318475-A1 | Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2009-12-24 | — | — | US | disclosed |
| WO-2008131858-A2 | USE OF ACYCLICALLY SUBSTITUTED FUROPYRIMIDINE DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTONIA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008131858-A2 | USE OF ACYCLICALLY SUBSTITUTED FUROPYRIMIDINE DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTONIA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-06 | — | — | WO | disclosed |
| EP-1966217-A1 | NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | Bayer HealthCare AG (DE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007079862-A1 | NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318475-A1 | Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof | DPYD, PNPO, TPMT | KDM4E 3800/4885ALDH1A1 318/4885HPGD 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.